FDA Adverse Event Death Summary report: N

ABBOTT AMPLATZER TORQVUE 45 X45 DELIVERY

MDR report key: 22882540 · Received August 25, 2025

Report

Report Number
MW5175143
Event Type
Death
Date Received
August 25, 2025
Date of Event
November 7, 2024
Report Date
August 19, 2025
Manufacturer
ABBOTT MEDICAL
Product Code
DQY
Adverse Event
Yes
Report Source
Voluntary report
Reporter Location
SC, US
Reporter Occupation
RISK MANAGER
Health Professional
Yes

Narratives

Description of Event or Problem · 0

TRANSFERRED FROM (B)(6) 11/7 AFTER PRESENTING WITH STROKE SYMPTOMS. PMH CABG, BIOPROSTHETIC AVR, CEREBRAL ANEURYSM AND (AFIB) ATRIAL FIBRILLATION (NO AC DUE TO FALL RISK). CT NEGATIVE FOR LARGE VESSEL OCCLUSION. RECEIVED TENECTEPLASE 0.25 MG/KG PRIOR TO TRANSFER DEACONESS HENDERSON. WITHIN 8 HOURS OF ADMINISTRATION, (B)(6) BECAME BRADYCARDIC WITH WORSENING (NIH SCORE) NATIONAL INSTITUTES OF HEALTH STROKE SCALE SCORE. REPEAT CT SHOWED NEW (ICH) INTRACEREBRAL HEMORRHAGE. (TXA) TRANEXAMIC ACID BOLUS WAS GIVEN AND (B)(6) WAS TRANSFERRED TO (B)(6) ON 11/9. FIBRINOGEN LEVEL 241 UPON ARRIVAL AND NO FURTHER TXA WAS GIVEN. NICARDIPINE DRIP WAS ORDERED FOR (BP) BLOOD PRESSURE CONTROL. CLOPIDOGREL STARTED 11/9. (B)(6) MAINTAINED ABILITY TO SPEAK, FOLLOW COMMANDS UNTIL BEGAN TO DEVELOP RESPIRATORY FAILURE ON 11/10. (B)(6) REQUIRED INTUBATION ON 11/11. DESPITE ATTEMPTS MADE TO OPTIMIZE CLINICAL CONDITION, (B)(6) CONTINUED TO FAIL (SBT) SPONTANEOUS BREATHING TRIAL. (B)(6) INDICATED SHE DID NOT WANT A TRACH SO TERMINAL EXTUBATING WAS DONE 11/22 AND (B)(6) EXPIRED SHORTLY AFTER. PATIENT CODES: 1891, 1751, 2484. REFERENCE REPORT #MW5175144, #MW5175145, #MW5175146.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2486775 ABBOTT AMPLATZER TORQVUE 45 X45 DELIVERY CATHETER, PERCUTANEOUS DQY ABBOTT MEDICAL 9174506

Patients

Seq Age Sex Outcome Treatment
1 80 YR Female Death CLOPIDOGREL.| NICARDIPINE.| TENECTEPLASE.